Subscribe

0

Piramal Pharma

Piramal Pharma Limited InFocus

Piramal Pharma FY25 Revenue Rises 12% to ₹9,151 Cr; EBITDA Up 15%

Piramal Pharma FY25 results: Revenue up 12% to ₹9,151 Cr, EBITDA grew 15% to ₹1,580 Cr with a 17% margin. PAT surged fivefold, and Net Debt/EBITDA improved to 2.7x.

By SMEStreet Edit Desk
Jul 03, 2025 11:00 IST 2 Min read
Piramal Pharma Limited InFocus
Piramal Pharma Q3FY25 Revenue Rises 13%, EBITDA Up 6%
By SMEStreet Edit Desk
Jan 29, 2025 10:20 IST 4 Min read
ajay piramal, Piramal Group, NBFC, InFocus
Piramal Pharma Ltd. to Acquire Manufacturer of peptide APIs Hemmo Pharmaceuticals
By SMEStreet Edit Desk
Apr 01, 2021 06:15 IST 2 Min read
CoVID-19 Vaccine, COVID Pandemic, Coronavirus LimeLight
CCI Approves Acquisition of Piramal Pharma's 20% Stakes Acquisition by CA Clover Intermediate
By SMEStreet Edit Desk
Sep 12, 2020 08:08 IST 1 Min read